CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

Proceedings of the National Academy of Sciences of the United States of America
Geertje J D van MierloR E Toes

Abstract

Adequate spontaneous activation of tumor-specific T lymphocytes in tumor-bearing hosts is rare, despite the expression of tumor antigens that are potentially highly immunogenic. For example, failure of the immune system to raise competent responses against established tumors expressing the human adenovirus E1A-antigen allows this tumor to grow in immunocompetent mice. We show that systemic in vivo administration of agonistic anti-CD40 antibodies into tumor-bearing mice results in tumor eradication mediated by CD8(+) T cells. Treatment resulted in a strong expansion and systemic accumulation of E1A-specific CTL and depended on CD40 expression on host cells, as the tumor was CD40(-), and therapy failed in CD40-deficient mice. Local intratumoral administration of anti-CD40 mAb is equally effective in licensing strong, systemic CTL immunity, resulting in the clearance of distant tumor nodules. Our data indicate that the immune response after cancer-host interactions can be directed toward competence, leading to the cure of established tumors merely by delivery of a CD40-dependent "license to kill" signal.

References

Jan 1, 1988·Annals of the New York Academy of Sciences·L A Husmann, M J Bevan
Jun 1, 1994·Current Opinion in Immunology·J P Allison
Nov 1, 1995·The Journal of Experimental Medicine·T C WuD M Pardoll
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·R E ToesW M Kast
Sep 1, 1996·The Journal of Experimental Medicine·C KurtsH Kosaka
Jul 7, 1997·The Journal of Experimental Medicine·S R BennettW R Heath
Oct 6, 1999·The Journal of Experimental Medicine·J P MedemaR Offringa
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·C KurtsW R Heath
Jul 6, 2000·Advances in Immunology·C J MeliefR Offringa
Jul 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J L CannonsT H Watts
Aug 30, 2001·Proceedings of the National Academy of Sciences of the United States of America·R M KedlS Dow

❮ Previous
Next ❯

Citations

Jul 5, 2003·International Journal of Hematology·John M Timmerman
Jan 25, 2008·Cancer Immunology, Immunotherapy : CII·Alexander L RakhmilevichPaul M Sondel
Sep 14, 2011·Cancer Immunology, Immunotherapy : CII·Adam J BogradPrasad S Adusumilli
Jun 24, 2006·Journal of Cancer Research and Clinical Oncology·Bernd KoppoldChristian Kurzeder
Mar 16, 2005·Current Opinion in Immunology·Willem W Overwijk
Nov 18, 2005·Surgery·Jason H ClarkeMartin D McCarter
May 16, 2003·Cellular Immunology·Rossella SartoriusPiergiuseppe De Berardinis
Sep 17, 2002·Methods : a Companion to Methods in Enzymology·Frank R de Gruijl
Jul 16, 2010·Immunology and Cell Biology·Connie JackamanDelia Jane Nelson
Sep 7, 2011·Immunology and Cell Biology·Nicholas S WilsonEugene Maraskovsky
Sep 10, 2005·Nature Biotechnology·Gregory P Adams, Louis M Weiner
May 13, 2008·Nature Reviews. Cancer·Klaus Strebhardt, Axel Ullrich
Oct 1, 2008·International Immunology·Connie JackamanDelia J Nelson
Dec 31, 2010·Current Opinion in Oncology·Jeffrey Weber
Aug 10, 2010·The Cancer Journal·Jedd D WolchokJeffrey S Weber
Jan 11, 2005·British Journal of Haematology·Toshiaki HayashiKenneth C Anderson
Jan 28, 2006·Journal of Virology·Geoffrey W StoneRichard S Kornbluth
Mar 6, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert H Vonderheide, Martin J Glennie
Nov 20, 2002·The Journal of Clinical Investigation·Roman A TumaEric G Pamer
Apr 10, 2008·The Journal of Clinical Investigation·Juliana HamzahRuth Ganss
Jan 1, 2014·Vaccines·Smita S Iyer, Rama R Amara
Jun 24, 2014·Journal of Immunology Research·Delia NelsonBruce Robinson
Jun 21, 2014·Future Oncology·Meaghan L KhanMitesh J Borad
Nov 26, 2002·Immunological Reviews·Cornelis J M MeliefRienk Offringa
Jul 23, 2004·Expert Opinion on Biological Therapy·Birgit C Schultes, Christopher F Nicodemus
Jun 25, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Geoffrey W StoneRichard S Kornbluth
Apr 13, 2010·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yan GeXue-Guang Zhang
Aug 7, 2009·Cytokine & Growth Factor Reviews·William K Decker, Amar Safdar
May 21, 2009·Experimental and Molecular Pathology·Rich-Henry SchabowskyHaval Shirwan
Oct 5, 2014·Advanced Drug Delivery Reviews·Zohreh Amoozgar, Michael S Goldberg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.